[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol; 2010 Dec 10;28(35):5210-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
  • PURPOSE: Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy.
  • We examined the value of purely preoperative chemotherapy in a phase III trial with strict preoperative staging and surgical resection guidelines.
  • PATIENTS AND METHODS: Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone.
  • RESULTS: This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III.
  • The International Union Against Cancer R0 resection rate was 81.9% after neoadjuvant chemotherapy as compared with 66.7% with surgery alone (P = .036).
  • Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Neoadjuvant Therapy / methods. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cardia / pathology. Cardia / surgery. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] JAMA. 2010 May 5;303(17):1729-37 [20442389.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):423-9 [12836016.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1248-52 [7552009.001]
  • [Cites] J Infus Chemother. 1996 Summer;6(3):123-6 [9229322.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2580-5 [17577037.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5062-7 [19770374.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):139-44 [10761793.001]
  • (PMID = 21060024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004099
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10-CA11488-29
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3020693
  •  go-up   go-down


2. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M: Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol; 2008 May;3(5):499-504
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality treatment of malignant pleural mesothelioma.
  • INTRODUCTION: Multimodality treatment has achieved significant success in local control and treatment of early-stage malignant pleural mesothelioma patients.
  • METHODS: We have instituted a trimodality treatment protocol consisting of extrapleural pneumonectomy, adjuvant high-dose (54 Gy) hemithoracic irradiation, and platin-based chemotherapy in a multi-institutional setting.
  • Preoperative pulmonary function tests, echocardiogram, chest computed tomography, and magnetic resonance imaging scans were performed in all patients.
  • Twelve patients completed all three treatments.
  • Eight patients had extrapleural lymph node involvement (internal mammary [n = 3], subcarinal [n = 2], pulmonary ligament [n = 1], diaphragmatic [n = 1], subaortic [n = 1]).
  • CONCLUSIONS: Trimodality treatment in malignant pleural mesothelioma seems to prolong survival in patients without lymph node metastasis.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449002.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Bogoevski D, Yekebas EF, Schurr P, Kaifi JT, Kutup A, Erbersdobler A, Pantel K, Izbicki JR: Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann Surg; 2004 Dec;240(6):993-1000; discussion 1000-1
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) distal hepatoduodenal ligament, 2) superior-anterior compartment, and 3) posterior-inferior.
  • Tissue sections of 148 lymph nodes classified as tumor free by routine histopathology were examined, using a sensitive immunohistochemical assay with the antiepithelial monoclonal antibody Ber-EP4 for tumor cell detection.
  • Analysis by compartment, from which the lymph nodes were collected, revealed that overall survival time (P = 0.006) and time to local recurrence (P = 0.015) depend on the presence of nodal microinvolvement in the superior-anterior compartment.
  • This could be a helpful tool in proper selection of patients for adjuvant chemotherapy.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1569-70 [7979715.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1827-32 [8083707.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Pancreas. 1997 Aug;15(2):154-9 [9260200.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):151-9 [9530884.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):583-90 [10091731.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):593-9 [10100711.001]
  • [Cites] Dig Surg. 1999;16(4):337-45 [10449979.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):870-3 [10555760.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):315-9 [12579265.001]
  • [Cites] Pancreas. 2003 May;26(4):315-21 [12717261.001]
  • [Cites] Int J Colorectal Dis. 2004 Sep;19(5):430-7 [14716495.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):386-97 [6615059.001]
  • [Cites] Br J Cancer. 1986 Oct;54(4):631-6 [3535864.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):409-11 [3311817.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Feb;23(2):137-47 [2450753.001]
  • [Cites] Pathology. 1989 Jan;21(1):11-5 [2474791.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):523-7 [1520589.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):493-8 [7680382.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • (PMID = 15570205.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  • [Other-IDs] NLM/ PMC1356515
  •  go-up   go-down


Advertisement
4. Fuks D, Bartoli E, Delcenserie R, Yzet T, Celice P, Sabbagh C, Chatelain D, Joly JP, Cheron N, Dupas JL, Regimbeau JM: Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol; 2009 Nov;24(11):1745-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice.
  • BACKGROUND AND AIM: The combination of photodynamic therapy and biliary stenting seems to be beneficial in the palliative treatment of unresectable cholangiocarcinoma.
  • We aimed to assess the accuracy of photodynamic therapy in a single centre.
  • METHODS: Fourteen selected patients, with jaundice related to unresectable cholangiocarcinoma, underwent photodynamic therapy and biliary stenting (with or without chemotherapy).
  • In case of malignant progression, photodynamic therapy was repeated.
  • Unresectability was related to a low Karnofski index (n = 2), peritoneal carcinomatosis (n = 4), vascular involvement (n = 3), invasion of the hepatoduodenal ligament (n = 2) and an under-sized liver remnant (n = 3).
  • Eight patients developed cholangitis.
  • The mean number of photodynamic therapy procedures was two (1-4).
  • Photodynamic therapy improved the Karnofski index in 64% of cases.
  • Six (42.8%) patients received concomitant chemotherapy (gemcitabine).
  • The median survival time was 13.8 [0.7-29.2] months.
  • CONCLUSION: These results confirm the beneficial effect of biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma in selected patients with jaundice.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / therapy. Cholangiopancreatography, Endoscopic Retrograde. Drainage. Jaundice / therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract Surgical Procedures / contraindications. Cholangitis / etiology. Dihematoporphyrin Ether / administration & dosage. Disease-Free Survival. Female. Humans. Injections, Intravenous. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pain Measurement. Palliative Care. Photosensitizing Agents / administration & dosage. Prospective Studies. Stents. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780885.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


5. Steed H, Oza A, Chapman WB, Yaron M, De Petrillo D: Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment. Int J Gynecol Cancer; 2004 May-Jun;14(3):546-50
Genetic Alliance. consumer health - Wolffian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment.
  • Female adnexal tumors of probable wolffian origin (FATWOs) are rare tumors arising in the broad ligament from the remnants of the mesonephric duct.
  • The tumor recurred within 2 years and was treated with multiple chemotherapy regimens, including a platinum-based drug, and surgery for progressive disease.
  • Gleevac therapy, a tyrosine kinase inhibitor, was prescribed, and she developed severe persistent lower abdominal pain 2 months later.
  • She is currently asymptomatic, without evidence of disease 10 months after surgery, continuing on Gleevac therapy.
  • There is limited knowledge about the optimal treatment for this neoplasm.
  • Our patient's favorable response to Gleevac therapy supports the concept of targeted molecular therapy in patients with c-kit-positive FATWO tumors.
  • [MeSH-major] Neoplasm Recurrence, Local / diagnosis. Peritoneal Neoplasms / diagnosis. Wolffian Ducts
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Combined Modality Therapy. Diagnosis, Differential. Enzyme Inhibitors / therapeutic use. Female. Humans. Protein-Tyrosine Kinases / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15228432.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


6. Karaca M, Sevinc A, Aydin A, Gocmen A, Buyukberber S, Camci C, Sari I: Female adnexal tumor of probable Wolffian origin diagnosed during the staging evaluation of extranodal diffuse large B-cell lymphoma. Leuk Lymphoma; 2005 Jun;46(6):929-33
Genetic Alliance. consumer health - Wolffian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female adnexal tumor of probable Wolffian origin (FATPWO) is a rare neoplasm arising within the leaves of broad ligament or hanging from it or a fallopian tube.
  • A 55-year-old female patient with the diagnosis of non-Hodgkin lymphoma is presented.
  • The staging procedure revealed a pelvic mass that was not regressed by chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasms, Adnexal and Skin Appendage / diagnosis. Wolffian Ducts / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytoplasm / metabolism. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019541.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Kanazawa Y, Tsuchiya H, Nonomura A, Takazawa K, Yamamoto N, Tomita K: Intentional marginal excision of osteosarcoma of the proximal fibula to preserve limb function. J Orthop Sci; 2003;8(6):757-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Caffeine-assisted chemotherapy was administered to three boys, ages 15, 17, and 11 years, and resulted in a complete response.
  • Two patients initially presented with peroneal nerve palsy that resolved completely with preoperative chemotherapy.
  • In two cases the collateral ligament and biceps tendon were reattached to the tibia with a spike washer or suture anchors, and in the third case they were reattached by suture only to the ligamentous and capsular structure of the tibia.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Combined Modality Therapy / methods. Follow-Up Studies. Humans. Male. Neoplasm Staging. Preoperative Care / methods. Recovery of Function. Risk Assessment. Sampling Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14648261.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Yoshidome H, Kato A, Miyazaki M: Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology; 2005 May-Jun;52(63):722-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination of the resected specimen revealed moderately differentiated adenocarcinoma compatible with cholangiocarcinoma, and lymph node metastases were found in the area of the hepatoduodenal ligament and the paraaortic region.
  • These recurrent tumors were completely eliminated by systemic chemotherapy with cisplatin or mitomycin C.
  • The patient is now doing well 6 years and 5 months after surgical treatment.
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retreatment

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966191.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Salemis NS, Tsiambas E, Liatsos C, Karameris A, Tsohataridis E: Small bowel intussusception due to a primary non-Hodgkin's lymphoma. An unusual presentation and clinical course. J Gastrointest Cancer; 2010 Dec;41(4):233-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Symptoms and signs are often vague and non-specific making a preoperative diagnosis difficult.
  • Computed tomography scan and ultrasonography findings were suggestive of small bowel intussusception.
  • RESULTS: Laparotomy revealed a jejuno-jejunal intussusception caused by a primary B cell non-Hodgkin's lymphoma 20 cm distal to the ligament of Treitz.
  • The patient refused postoperative adjuvant chemotherapy.
  • Despite chemotherapy, he died of disseminated progressive disease 7 months later.
  • Appropriate investigations can lead to a prompt preoperative diagnosis.
  • Resection without prior reduction is the treatment of choice.
  • Our patient's refusal of postoperative adjuvant chemotherapy likely resulted in relapse of the disease in another part of the gastrointestinal tract.
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1971 May;121(5):531-5 [5557762.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):339-44 [15101721.001]
  • [Cites] Int J Hematol. 2008 May;87(4):375-81 [18409078.001]
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):390-5 [10195723.001]
  • [Cites] Radiol Clin North Am. 2008 Mar;46(2):287-312, ix [18619382.001]
  • [Cites] J Gastrointest Cancer. 2009;40(3-4):79-82 [19937400.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):45-7 [10652920.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):230-6 [7469558.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • [Cites] Clin Radiol. 1998 Jan;53(1):53-7 [9464437.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):834-9 [15951987.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] J Int Med Res. 2007 May-Jun;35(3):406-15 [17593870.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):343-7 [12612513.001]
  • (PMID = 20411355.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL: Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol; 2003 Apr;169(4):1295-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Enteric type adenocarcinomas arising in the dome of the bladder or along the urachal ligament are uncommon.
  • Specifically, we sought to evaluate the importance of extent of disease, surgical characteristics and systemic therapy on clinical outcome.
  • RESULTS: Of the 42 patients 7 had clinically evident metastases at diagnosis and 35 had resectable disease that was managed initially with surgery.
  • Overall survival from diagnosis for all 42 patients was 46 months with 40% surviving at 5 years.
  • Median survival from recognition of metastatic disease was 24 months in 26 patients in whom metastases ultimately developed.
  • Chemotherapy for metastatic disease produced only 4 significant responses, including 3 of 9 patients treated with 5-fluorouracil and cisplatin containing regimens.
  • Chemotherapy appropriate for enteric type adenocarcinoma can induce objective responses but meaningful improvement in survival is not yet demonstrated.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cystectomy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Texas

  • Genetic Alliance. consumer health - Urachal cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12629346.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA91846
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Yan TQ, Yang RL, Guo W: [The clinical outcome of proximal fibular osteosarcoma with en-bloc resection]. Zhonghua Wai Ke Za Zhi; 2008 May 1;46(9):661-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean age at diagnosis was 16 (9-23) years old.
  • Histopathological diagnosis were obtained by trut-cut biopsy, Enneking surgical stages of 12 lesions were as follows: 11 grade II B and 1 grade III.
  • Induction chemotherapy was applied to all patients except one who left the hospital after the biopsy.
  • Of 11 patients, 8 were performed Malawer type I resection, and 3 type II.
  • All patients continued to get postoperative chemotherapy.
  • No knee instability is found in this group after great care is taken for proper reconstruction of lateral collateral ligament and reinsertion of biceps femoris tendon on the lateral condyle of tibia.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Survival Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956716.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Junginger T, Kneist W, Seifert JK: [Surgical treatment of colorectal liver metastases]. Zentralbl Chir; 2003 Nov;128(11):911-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of colorectal liver metastases].
  • [Transliterated title] Chirurgische Therapie von Lebermetastasen kolorektaler Karzinome.
  • Resection is the only curative treatment of colorectal liver metastases proofed by a long-term follow-up.
  • The resection is not indicated in cases with non resectable extrahepatic tumours and lymph node metastases distal the hepatoduodenal ligament.
  • Aims of new concepts of operative therapy are the improvement of resectability by preoperative portal vein embolization, the resection combined with local destructive methods and preoperative chemotherapy.
  • Additionally, new drugs for adjuvant treatment after resection of metastases are studied.
  • The interdisciplinary discussion of the course before and after therapy is essential for the individual optimal treatment.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Hepatectomy. Humans. Liver Cirrhosis / complications. Lymphatic Metastasis / radiography. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Patient Selection. Postoperative Complications. Prognosis. Prospective Studies. Randomized Controlled Trials as Topic. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14669111.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 72
  •  go-up   go-down


13. Siefker-Radtke A: Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther; 2006 Dec;6(12):1715-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The urachal ligament is an embryologic remnant connecting the dome of the bladder to the umbilicus via the ligamentum commune.
  • Although there are no prospective clinical trials reported to date, large single-institution reports suggest surgical resection with a partial cystectomy and en bloc resection of the urachal ligament with umbilicus as the treatment of choice in the setting of localized disease.
  • Although there is currently no definitive role for neoadjuvant or adjuvant chemotherapy in this tumor, risk factors predicting progression may allow for the selection of patients at higher relapse risk for prospective studies.
  • There is no standard chemotherapy regimen for these patients; however, there is new-found hope with a currently accruing clinical trial exploring a 5-fluorouracil-based chemotherapy combination in this patient population.
  • [MeSH-major] Adenocarcinoma / therapy. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cisplatin / administration & dosage. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Hematuria / etiology. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Umbilicus / surgery. Urachal Cyst / pathology. Urachal Cyst / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181485.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 29
  •  go-up   go-down


14. Maeda M, Kobayashi A, Kawasoe J, Nakagawa J, Kobayashi T, Takehana T, Yonezawa K, Miyashita T: [A case of rupture of post-gastrectomy afferent loop obstruction due to invasion by pancreatic cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2364-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 77-year-old man with history of distal gastrectomy with Billroth II reconstruction for peptic ulcer disease performed 55 years ago was admitted to our hospital for diarrhea and abdominal pain.
  • Abdominal computed tomography revealed a dilatation of the afferent loop and the duodenum, and a low density mass located in the body of the pancreas, which invaded the gastro-jejunal anastomosis site as well as the celiac axis and the superior mesenteric artery.
  • After a while, the patient complained a severe abdominal pain, and an emergency surgery was performed under the diagnosis of rupture of the afferent loop.
  • At laparotomy, a perforation of the jejunum located at a 15 cm anal side from Ligament of Treitz was found, and Braun's anastomosis was performed using the perforated site.
  • The patient was treated with chemotherapy and survived for 15 months after the operation.
  • [MeSH-minor] Acute Disease. Aged. Humans. Jejunum / pathology. Male. Neoplasm Invasiveness. Rupture, Spontaneous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224574.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Miao M, Kong CZ, Li ZH, Liu XK, Sun ZX: [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 May 15;47(10):728-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma].
  • OBJECTIVE: To investigate the clinical methods for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma.
  • Technique B was dissection along the vas deferens to the bladder wall circumferentially around the ipsilateral ureteral orifice and division of the lateral vesical ligament to reach the seminal vesicle.
  • Prophylactic intravesical chemotherapy included 3 method.
  • Method 1 was intraoperative intravesical chemotherapy and then administrated once a week, 10 times in total.
  • Method 2 was intraoperative intravesical chemotherapy and then administrated once a week from the 4(th) week after operation, 10 times in total.
  • Method 3 was intravesical chemotherapy was given once a week from the 4(th) week after operation, 10 times in total.
  • The time of follow-up was 1 to 10 years with regular cystoscopy.
  • The postoperative recurrence rates of bladder cancer in patients using 3 kinds of intravesical chemotherapy regimen were 17.9% (11/67), 20.8% (10/48) and 33.3% (17/51), respectively.
  • There was significant difference between the recurrence rates of patients using method 1 and method 3 intravesical chemotherapy (P < 0.05).
  • CONCLUSION: Complete removal of the bladder mucosa circumferentially around the ureteral orifice, administration of the intraoperative intravesical chemotherapy instillation and instillation once a week may be a useful approach to reduce the recurrence of bladder cancer after operation for renal pelvic carcinoma.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Postoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615202.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Asenov DR, Kaga K, Tsuzuku T: Changes in the audiograms of a nasopharyngeal cancer patient during the course of treatment: a temporal bone histopathological study. Acta Otolaryngol; 2007 Oct;127(10):1105-10
Genetic Alliance. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the audiograms of a nasopharyngeal cancer patient during the course of treatment: a temporal bone histopathological study.
  • This report shows the changes that occurred in consecutive audiograms of a patient who underwent chemotherapy and radiotherapy for nasopharyngeal cancer and the histopathological examination of the temporal bones.
  • Both conductive and sensorineural hearing loss developed, but followed different modes of progression.
  • In the left ear, an air-bone gap appeared and deepened, while in the right ear, severe conductive hearing loss was present upon admission and improved after treatment.
  • The main changes in the cochlea were vascular stria degeneration, spiral ligament atrophy, and spiral ganglion cell depletion, while the hair cells were only occasionally missing.
  • [MeSH-minor] Aged. Combined Modality Therapy / methods. Hearing Loss, Conductive / etiology. Hearing Loss, Conductive / physiopathology. Hearing Loss, Sensorineural / etiology. Hearing Loss, Sensorineural / physiopathology. Humans. Male. Neoplasm Invasiveness. Photomicrography. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851900.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


17. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol; 2003 Aug;90(2):390-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients (408) with stage IIIC epithelial ovarian cancer had cytoreductive surgery before systemic platinum-based combination chemotherapy.
  • (1) right upper quadrant (diaphragm/hepatic, and adjacent peritoneal surfaces), (2) left upper quadrant (omentum/gastro-colic ligament, spleen, stomach, transverse colon, splenic flexure of colon), (3) pelvis (reproductive organs, recto-sigmoid, pelvic peritoneum), (4) retroperitoneum (pelvic/aortic nodes), and (5) central abdomen (small bowel, ascending/descending colon, mesentery, anterior abdominal wall, pericolic gutters).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893206.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Liang JT, Lai HS, Lee PH: Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer. Ann Surg Oncol; 2007 Jun;14(6):1878-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Our previous randomized clinical trial comparing the laparoscopic medial-to-lateral dissection with the more classic lateral-to-medial approach for resection of rectosigmoid cancer showed that the medial approach reduces the operative time and the postoperative proinflammatory response.
  • METHODS: A total of 104 patients (from December 2000 to January, 2005) with advanced right-sided colon cancer (TNM stage II: n = 56; stage III: n = 48) requiring a curative right hemicolectomy were subjected to the laparoscopic medial-to-lateral approach that included initial exploration and ligation of ileocolic, right colic, and middle colic vessels in no-touch isolation fashion, subsequent medial-to-lateral extension of retroperitoneal dissection along Gerota fascia, opening of lesser sac by transection of gastrocolic ligament, and the final mobilization of hepatic flexure and lateral attachments of ascending colon (Fig. 1).
  • Postoperatively, adjuvant chemotherapy with Mayo Clinic Regimen was given in patients with stage III diseases.
  • RESULTS: The laparoscopic medial-to-lateral approach for a curative right hemicolectomy can be preformed with acceptable operation time (192.6 +/- 32.8 min, mean +/- standard deviation) and little blood loss (48.4 +/- 14.4 ml) through a small wound (6.0 +/- 0.8 cm).
  • During the follow-up periods (median: 30 months, range 6-55 months), recurrence of tumor developed in 6 (10.7%) of stage II and 10 (20.8%) of stage III patients, with liver metastasis in six patients, lung metastasis in 4, liver and lung metastasis in 1, intraperitoneal recurrence in 2, bone metastasis in 1, brain metastasis in 1, and port-site recurrence in 1.
  • [MeSH-minor] Blood Loss, Surgical. Chemotherapy, Adjuvant. Dissection / methods. Feasibility Studies. Follow-Up Studies. Hospitalization. Humans. Ileus / etiology. Ligaments / surgery. Ligation. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Pain, Postoperative / etiology. Postoperative Complications. Prospective Studies. Recovery of Function / physiology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377832.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tozzi R, Köhler C, Ferrara A, Schneider A: Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol; 2004 Apr;93(1):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes.
  • PATIENTS AND METHODS: Between 05-1996 and 06-2003, 24 patients with ovarian cancer FIGO stage IA-B underwent either primary treatment or completion of staging by laparoscopy.
  • Laparoscopic staging was performed according to the FIGO guidelines, which entails one-sided oophorectomy or bilateral salpingo-ophorectomy with laparoscopic-assisted vaginal hysterectomy, pelvic lymphadenectomy, infrarenal para-aortic lymphadenectomy, complete resection of the infundibulo-pelvic ligament, appendectomy and partial omentectomy.
  • Mean operative time was 166 min (range 118-206) for completion of staging and 182 min (range 141-246) for primary surgery.
  • One out of 24 patients (4.1%) developed chylos ascites postoperatively, which was managed conservatively.
  • Five out of 24 patients (20.8%) received adjuvant chemotherapy after a median time of 7 days (mean 5-14) following surgery.
  • Two out of 24 patients (8.3%) developed recurrence, which was treated with resurgery and chemotherapy.
  • [MeSH-minor] Adult. Aged. Female. Humans. Laparoscopy / methods. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15047236.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dawes LG: Gallbladder cancer. Cancer Treat Res; 2001;109:145-55
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prognostic factors that influence the success of aggressive surgical therapy include depth of invasion, extent of hepatic infiltration, histologic grade, presence of venous, lymphatic or perineural invasion, and lymph node metastasis.
  • Tumors with tumor limited to the subserosal layer, hepatic infiltration that is only 5 mm or less, papillary or well differentiated adenocarcinomas, tumors with no venous, lymphatic or perineural invasion and lymph node metastasis limited to the hepatoduodenal ligament have the best prognosis with surgery (15, 16, 36).
  • Earlier detection or more effective chemotherapy will be needed to significantly improve the prognosis of this disease.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11775433.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 36
  •  go-up   go-down


21. Urahashi T, Yamamoto M, Ohtsubo T, Katsuragawa H, Katagiri S, Takasaki K: Liver metastases with massive portal venous tumor thrombi from colorectal cancer: can be treated by surgical resection? Hepatogastroenterology; 2007 Jan-Feb;54(73):210-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: The surgical treatments for liver metastases from colorectal cancer with massive portal venous tumor thrombi were evaluated.
  • (1) the circumferential incision of the first branch of the portal vein and removal of the exposed tumor thrombi with ring forceps and suction, (2) temporary clamping of the distal end, (3) dilatation of the round ligament and the venous cannula was inserted into the umbilical portion, (4) washing out of the residual tumor thrombi, (5) declamping of the distal end and closing suture of the cut end of the portal branch.
  • The intra-arterial catheter devices were implanted in four patients in order to receive adjuvant chemotherapy.
  • The mean survival time was 14.4 months and the overall 1-year survival rate was 20.0 percent.
  • CONCLUSIONS: Surgical resection for this disease may bring longer survival rates for some patients, but not be an effective therapeutic option in our series.
  • We should create other adjuvant therapies to improve these survival rates.
  • [MeSH-minor] Aged. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Thrombectomy


22. Caudry M, Ratoanina JL, Escarmant P, Maire JP: [Target volume in radiotherapy of gastric adenocarcinoma]. Cancer Radiother; 2001 Oct;5(5):523-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les volumes-cibles de la radiothérapie des adénocarcinomes gastriques.
  • A GTV should be considered in preoperative or exclusive radiation therapy.
  • (1) contiguous microscopic extension from deeply invasive T3 and T4 tumors, that remain amenable to local sterilization with doses of 45-50 Gy, delivered in a CTV including the peritoneal cavity at the level of the gastric bed, and under the parietal incision;.
  • (2) true "peritoneal carcinomatosis", with widespread seeds, where chemotherapy (systemic or intraperitoneal) is more appropriate.
  • In distal and proximal tumors, involvement of resection margins is of poor prognosis--a radiation boost must be delivered at this level.
  • In tumors invading the distal esophagus, a more complete coverage of mediastinal lymph nodes should be considered, especially in patients in good general condition.
  • In contrast, for distal tumors, the hepatic pedicle and the hepatoduodenal ligament should be included whereas the splenic area could be spared.
  • CONCLUSION: Planning the treatment of gastric cancer remains difficult; target volumes must be customized by experienced radiation oncologists according to tumoral and clinical situation.
  • [MeSH-minor] Dose Fractionation. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715304.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


23. Levine PH, Wei XJ, Gagner JP, Flax H, Mittal K, Blank SV: Pleomorphic liposarcoma of the uterus: case report and literature review. Int J Gynecol Pathol; 2003 Oct;22(4):407-11
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparotomy revealed a 15-cm, oval, well-circumscribed mass emanating from the posterior cervix and left uterosacral ligament.
  • Microscopic examination revealed a variety of patterns and cell types characteristic of liposarcoma that included myxoid/round cell, storiform/pleomorphic, epithelioid, and spindle cell areas.
  • Although a variety of uterine tumors have been associated with tamoxifen treatment, this appears to be the first example of tamoxifen-associated uterine liposarcoma.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14501826.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 29
  •  go-up   go-down


24. Qin H, Cai J, Fang J, Xu H, Gong Y: Could MTA be a novel medicine on the recurrence therapy for GCTB? Med Hypotheses; 2010 Feb;74(2):368-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could MTA be a novel medicine on the recurrence therapy for GCTB?
  • Surgical treatment of GCTB is associated with high morbidity, and local recurrence.
  • MTA is a powder aggregate containing mineral oxides with a good biological action and may facilitate the regeneration of the periodontal ligament and formation of bone.
  • MTA may be the therapy of choice for primary as well as recurrent giant cell tumors of bone.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / physiopathology. Giant Cell Tumor of Bone / drug therapy. Giant Cell Tumor of Bone / physiopathology. Glutamates / administration & dosage. Guanine / analogs & derivatives. Neoplasm Recurrence, Local / physiopathology. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656634.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


25. Shone N, Duggan MA, Ghatage P: Granulosa cell tumour of the broad ligament. Pathology; 2003 Jun;35(3):265-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumour of the broad ligament.
  • [MeSH-major] Broad Ligament / pathology. Genital Neoplasms, Female / pathology. Granulosa Cell Tumor / secondary. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Palliative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506976.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement